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In 2012, Infectious Agents and Cancer commissioned a thematic series collection of articles on Prevention of HPV
related cancer. The articles have attracted wide interest and stimulated debate, including about the utility of
vaccines in cancer control. The application of vaccines to cancer control fulfills a promise envisioned at the turn of
the 20th century when remarkable experiments showed that some cancers were caused by infections. This
suggested the possibility of applying infection-control strategies to cancer control. Vaccines represent the most
practical cost-effective technology to prevent wide human suffering and death from many acute infectious
diseases, such as small pox or polio. Hitherto applied to control of acute fatal infections, vaccines, if developed,
might provide a potent way to control cancer. The articles in the HPV thematic series show success in developing
and applying a vaccine against human papilloma virus (HPV). A vaccine is also available against hepatitis B virus
(HBV), which causes liver cancer. These vaccines augment the tools available to control the associated cancers.
Scientific endeavor continues for six other cancer-associated infections, mostly viruses. Not surprisingly, debate
about the safety of vaccines targeting cancer has been triggered in the scientific community. Questions about
safety have been raised for those populations where other means to control these cancers may be available.
Although it is difficult to quantify risk from vaccines in individuals where other cancer control services exist, it is
likely to be low. Vaccines are much safer today than before. Technological advancement in vaccine development
and manufacture and improved regulatory review and efficient distribution have minimized substantially the risk for
harm from vaccines. Formal and informal debate about the pros and cons of applying vaccines as a cancer control
tools is ongoing in scientific journals and on the web. Infectious Agents and Cancer encourages evidence-based
discussion to clarify understanding of the role of vaccines in cancer control. In a similar vein, the journal will not
consider anecdotal reports and rhetorical arguments because they are unlikely to inform policy, regulation, or the
public.Editorial
In 2012, Infectious Agents and Cancer commissioned a
thematic series collection of articles on Prevention of
HPV related cancer. The articles have attracted wide
interest and stimulated debate, including about the uti-
lity of vaccines in cancer control. The application of vac-
cines to cancer control fulfills a promise envisioned at
the turn of the 20th century when remarkable experi-
ments showed that some cancers were caused by infec-
tions. Vaccines represent one of the most successful
medical advances of all time. Vaccines prevent suffering
and death from many acute infectious diseases for which* Correspondence: fmbuonaguro@tin.it
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distribution, and reproduction in any mediuma vaccine can be developed. The application of vaccines
on a global scale has been dramatically expanded as mo-
dern knowledge, techniques, management and policy
frameworks have led to more cost-effective production
and delivery pipelines to populations who need them.
For example, vaccination programs, mandated by law or
applicable regulations, have diminished morbidity and
mortality from many infectious diseases that previously
were scourges and posed severe economic burdens (such
as measles, polio, diphtheria, Haemophilus influenzae
type b and pneumococcal infections). Global vaccination
programs have eradicated smallpox and reduced polio-
myelitis transmission to low levels such that eradication
is feasible [1]. With this success, the possibility to con-
trol highly variable pathogens (i.e. HIV, influenza virus,
malaria etc.) through vaccines has emerged. In theioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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fections, particularly viruses, is motivated, in part, by the
possibility of preventing such cancers through vacci-
nation. By the turn of the 21st century, 8 human viruses,
including Epstein-Barr virus, human papilloma viruses
(HPV), hepatitis B and C virus (HBV and HCV), had
been linked to cancer in humans. Vaccines have been
developed and are being delivered to populations against
two of these viruses - HBV and HPV. These vaccines are
dramatically reducing the incidence of new infections
and they are expected to dramatically reduce the risk of
associated cancers, namely, liver and cervical.
The science of vaccines and their application, however,
has had a long history rooted in trial and error approaches,
which may be relevant today. The “low dose” smallpox in-
oculation practices reported by Wang Zhangren's Douzhen
jinjing lu (痘疹金鏡錄) in 1579 [2] and the introduction of
“attenuated” cowpox vaccination to prevent small pox
by Dr John Fewster in 1765 [3], standardized by Edward
Jenner in 1798 [4], would probably not stand scientific
scrutiny in today’s world. However, even at this time,
fear of “inoculations” was already present, as noted in
the cartoon from 1802 (Figure 1). A similar fear of vac-
cines exists today in some populations. Notwithstanding
those fears, those pioneering efforts led directly to ad-
vances in knowledge and improvement in techniques to
study immunity and to the development of vaccines, in-
cluding the elimination of the arm-to-arm vaccinia
transfer (associated with the high risk of syphilis trans-
mission) and the worldwide implementation of the calf
lymph vaccine developed by Galbiati in 1810 [5,6].
Pasteur’s discovery of an attenuated Rabies vaccine in
1885 [7] was a triumph against a frightening disease.Figure 1 The Cow-Pock—or—the Wonderful Effects of the New Inocula
expressing the popular dread of vaccination.The development of attenuated or inactivated vaccines
against yellow fever, measles, rubella, and mumps, as well
as the bacterial disease typhoid, Mycobacterium tubercu-
losis (BCG) Yersinia pestis (EV) followed in rapid succes-
sion. Attenuated vaccines induce transient growth of the
virus in the host. This elicits durable immunity in the host
and renders booster doses unnecessary. Attenuated vac-
cines, however, may cause harm when the attenuated
viruses revert and become virulent again. In response, de-
velopment of vaccines from inactivated – or killed-
viruses eliminated the risk of reversion. Examples of
inactivated vaccines include those used against influenza,
cholera, bubonic plague, polio, hepatitis A, and rabies. Be-
cause transient growth does not occur with inactivated
vaccines, booster doses are needed to elicit adequate
immunity.
More recently, modern vaccines have relied on only
components of the pathogen - the so-called subunits or
conjugate vaccines. In some cases, these vaccines target
inactivated toxins, such as the vaccines against tetanus
and diphtheria. The subunits used are generally from a
part of the pathogen exposed to the outside environ-
ment. Examples of subunit vaccines include the first
generation of HBV vaccine, the current anti-HPV vac-
cines and Haemophilus influenzae type B vaccine. Since
the’ 80s, innovation in vaccine technology has included
production of subunit proteins synthetically by recom-
binant technology, which has replaced the crude method
of extraction from the pathogen, and vastly improved
the safety of modern vaccines.
Viewed in today’s terms, vaccines are distant from the
blind “trial and error” inoculations of the 17th or 18th cen-
tury. Today, vaccines are synonymous with prevention oftion! caricature printed by James Gillray in 1802, humorously
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past, like small pox or polio, have been subdued through
vaccines. Vaccines represent hope, as well, to control more
infections that still afflict millions, if not billions, world-
wide. These include infections that cause human cancer,
which are attributable to infections in 20-30% of cases.
Vaccines have been developed against HBV and HPV,
suggesting that cautious optimism may be warranted.
Nonetheless, as in the early days, the safety of vaccines
remains a subject to intense debate. Caution is urged
when deploying vaccines to identify and deal with life-
threatening side effects that may emerge. Responsible
discussion is also urged to tone down alarmist messages
that may mislead the public to reject vaccines and in-
crease their health risks.
Debate in the scientific literature is vital to identify
and act on such concerns. It also provides neutral but
authoritative reassurance to the general population.
Specific questions related to individual vaccines arise
from time to time and they need to be addressed in a
sound and timely manner. Infectious Agents and Can-
cer is facilitating such a debate now. In their letter
responding to an article by Serrano et al. on the anti-
HPV nonavalent vaccine [8], Tomljenovic, et al. [9]
question the safety of HPV vaccines and whether, if at
all, they can be recommended for cervical cancer pre-
vention. In her response, Dr de Sanjosè, a leading epi-
demiologist on HPV and guest Editor for the HPV
Series, has provided robust responses to the questions
raised by Tomljenovic, et al. [9]. The issues emerging
from the current HPV debate, but relevant for vac-
cines against other oncogenic viruses, can be summa-
rized as follows:
1) Given that cancer takes several decades to develop,
can intermediate states in the pathway to cancer be
used to evaluate the efficacy, and recommend the
use, of anti-cancer vaccines?
2) Given that there may be dangers associated with
vaccination, including the anti-HPV vaccines, do the
dangers outweigh the benefits?
The scientific community addresses the first issue and
regulatory Agencies address the second issue.
For anti-HPV vaccines, scientists have carefully con-
sidered virologic (i.e. virus isolation, virus titer) and
cytological/histological end-points (i.e. pre-invasive and
invasive lesions) and the natural history of disease. They
have identified intermediate states, called pre-malignant
end-points, which occur in the long interval between ex-
posure to infection and cancer development. de Sanjosè
and others explain this point adequately. A reduction of
pre-invasive lesions represents a reliable intermediate
end point for anti-HPV vaccines.To weigh benefits versus risks requires unequivocal evi-
dence of causation. HPV infection is necessary for HPV-
related cancers to develop. This conclusion is based on
evidence adduced by independent panels constituted by
the International Agency for Research on Cancer, a part of
the World Health Organization [10]. This conclusion is
the basis for the scientific investment in studies designed
to interrupt HPV transmission targeting the most im-
portant viral subtypes for cancer, so called high-risk geno-
types, e.g., HVP 16 and 18. After many years of careful
study, scientists have accurately estimated the efficacy of
anti-HPV vaccines. Observational studies, using cancer
registry data, may provide indirect evidence of efficacy
against cancer by showing sustained reduction in cancer
in ten-fifteen year time frame.
In the letter by Tomljenovic et al. [9], the authors ques-
tion the logic of vaccinating girls to prevent long-term
risks against cervical cancer. They assert that it is wrong
to justify the vaccination against oncogenic virus to a pre-
invasive cancer endpoint. They assert that vaccines un-
necessarily expose young girls to harm. They question the
entire process of vaccine development as being heavily
tilted against unsuspecting vaccine recipients. However,
questions of beneficence of vaccines have been exhaus-
tively discussed before and will continue to be. P. Offit, in
his article in the New England Journal of Medicine [11]
and, in much greater detail, in his book Vaccinated: One
Man’s Quest to Defeat the World’s Deadliest Diseases
(HarperCollins, 2007) [12], outlines the quest to subdue
disease through vaccination. As discussed above, the case
of chronic infections introduces a further degree of com-
plexity. It requires the use of validated intermediate states
for cancer to evaluate vaccine efficacy. The intermediates
states are very early stages of cancer initiation and pro-
gression. The intermediate states are already incorporated
into cancer control strategies that rely in screening healthy
women, identifying those with intermediate states and of-
fering them early cancer care. It is therefore reasonable to
assume demonstration that administering anti-HPV vac-
cines to young women reduces HPV infection and associ-
ated intermediate states indicates that the vaccine will
ultimately have a positive impact on cancer morbidity.
The intermediate endpoints can be to screen and identify
individuals at high risk for cancer who can be offered spe-
cific treatments to prevent cancer as an alternative. Some
countries, such as Italy and Australia, have adopted a po-
licy for universal free vaccination at 11-years. Recent data
from Australia for the period 2004 to 2011 demonstrated
significant declines in the proportion of young women
found to have genital warts and the no new cases of geni-
tal warts in vaccinated women [13]. These results show
clearly that the human papillomavirus vaccine has a high
efficacy outside of the trial setting and its addition to the
already available cervical cancer control strategies, such as
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older women for cancer control is controversial and not
widely recommended [14].
In summary vaccination technology coupled with vast
improvements in distribution infrastructure had helped
reduce morbidity and mortality from acute infections, and
is poised to play a major role in cancer control. Improve-
ments in recombinant technology and better choice of
adjuvant formulations have made vaccines much safer
[15,16]. Safety of vaccines will remain a matter of concern
for many and debate will continue to inform scientists,
public health managers, regulators, and users. Infectious
Agents and Cancer welcomes and encourages reasonable
debates with substantial data and authoritative reviews,
which can be considered for publication.
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